Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2 2Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 14OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 685Breast Neoplasms 584Neoplasms 468Colorectal Neoplasms 298Prostatic Neoplasms 262Neoplasm Metastasis 256Melanoma 241Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 195Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 141Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Head and Neck Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Small Cell Lung Carcinoma 95Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 76Triple Negative Breast Neoplasms 72

Interventions

XENP 1595 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Cognitive Dysfunction × Clear all
NCT06745583 2026-04-09

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Phase 2 Recruiting
15 enrolled
Lymphoid

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡